Lu-PSMA-617

Novartis' radiopharma drug wins approval in tough-to-treat prostate cancer patients
Endpoints
Wed, 03/23/22 - 11:01 pm
Novartis
Lu-PSMA-617
radioligand
prostate cancer
Novartis sets the tone for the radiopharma push with a prized acquisition winning breakthrough therapy designation
Endpoints
Thu, 06/17/21 - 11:09 am
Novartis
radiopharmaceuticals
breakthrough therapy
FDA
Lu-PSMA-617
Pharma/Biotech Stocks to Watch This Prostate Cancer Month
Yahoo/Zacks.com
Sun, 09/16/18 - 02:16 pm
prostate cancer
JNJ
Zytiga
Erleada
Pfizer
Astellas
Xtandi
AbbVie
Lupron
Endocyte
Lu-PSMA-617